NRX Pharmaceuticals Inc. (NRXP) stock prices soared 9.37% as of the market closing on August 26th, 2021. This brought the price per share to USD$14.12.
NXRP Stock’s Collaboration
August 26th, 2021 saw NRXP stock announce the signing of an agreement with Cardinal Health. The agreement will see the facilitation of the provision of third-party logistics and distribution of ZYESAMI. This is pending the potential Emergency Use Authorization (EUA) approval by the United States Food and Drug Administration. May 2021 saw the company submit an application for EUA to the FDA for their proprietary treatment for patients suffering from Critical Covid-19 with respiratory failure.
Focus of NXRP Stock’s Partnership
The strategic collaboration creates an efficient and highly flexible logistics and distribution model for NRXP stock. The partnering company’s expertise will allow the treatment to be delivered to patients in intensive care units in a rapid fashion. This is essential as the limiting of time to treatment is crucial. The partnership also allows for the company to continue focusing on responding to requests from the FDA in regard to the company’s EUA application for ZYESAMI.
About NRXP Stock’s Partner
Cardinal Health Specialty Pharmaceutical Distribution will be the exclusive distributor for ZYESAMI, facilitating the provision of wide access to hospitals for the much needed treatment. Cardinal Health has access to one of the largest healthcare supply chains, servicing more than 90% of the hospitals in the United States. The company has more than two decades of supporting the rapid delivery of life-saving medicines. Furthermore, the partnering company’s Third-Party Logistics Services will support warehousing and distribution, as well as full order to cash, and necessary title model services.
Addressing the Global Pandemic
The ongoing impact of the global coronavirus pandemic requires the proliferation of more innovative, effective, and FDA-approved therapies for critically-ill patients suffering from respiratory failure. The partnering company continues to allocate resources towards ensuring Covid-19 patients get access to treatment in a timely and efficient manner.
Future Outlook for NRXP Stock
With the world hurtling towards universal immunizations, NRXP stock is poised to capitalize on the scope of opportunities presented to it. The company is keen to leverage the resources at its disposal to facilitate the accelerated proliferation of its flagship treatment. Investors are hopeful that management will be able to usher in organic growth over the long term.
